Japan

Last Updated 16 May 2022.

4 Vaccines Approved for Use in Japan

• Takeda
  TAK-019 (Novavax formulation)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 1 country

  3 trials in 1 country

  Approval Source: reuters.com

  Protein Subunit

• Pfizer/BioNTech
  Comirnaty

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 146 countries

  78 trials in 26 countries

  Approval Source: japantimes.co.jp

  RNA

• Takeda
  TAK-919 (Moderna formulation)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 1 country

  2 trials in 1 country

  Approval Source: takeda.com

  RNA

• Oxford/AstraZeneca
  Vaxzevria

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 140 countries

  63 trials in 30 countries

  Approval Source: astrazeneca.com

  Non Replicating Viral Vector

14 Vaccines in Clinical Trials in Japan

• Shionogi
  S-268019

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  7 trials in 2 countries

  Protein Subunit

• Takeda
  TAK-019 (Novavax formulation)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 1 country

  3 trials in 1 country

  Protein Subunit

• Medicago
  Covifenz

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 1 country

  6 trials in 6 countries

  VLP

• AnGes
  AG0302-COVID19

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  8 trials in 1 country

  DNA

• Daiichi Sankyo Co Ltd
  DS-5670a

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  5 trials in 1 country

  RNA

• Moderna
  Spikevax

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 86 countries

  63 trials in 22 countries

  RNA

• Pfizer/BioNTech
  Comirnaty

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 146 countries

  78 trials in 26 countries

  RNA

• Janssen (Johnson & Johnson)
  Ad26.COV2.S

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 111 countries

  21 trials in 23 countries

  Non Replicating Viral Vector

• Oxford/AstraZeneca
  Vaxzevria

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 140 countries

  63 trials in 30 countries

  Non Replicating Viral Vector

• KM Biologics Co Ltd
  KD-414

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  4 trials in 1 country

  Inactivated

• AnGes
  AG0301-COVID19

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  DNA

• Elixirgen Therapeutics Inc
  EXG-5003

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• Takeda
  TAK-919 (Moderna formulation)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 1 country

  2 trials in 1 country

  RNA

• VLP Therapeutics Japan
  VLPCOV-01

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  RNA